产品说明书
Vitexin
 |
同义名 : | Orientoside;Apigenin-8-C-glucoside;Vitexin, Apigenin 8-C-glucoside |
| CAS号 : | 3681-93-4 | |
| 货号 : | A400559 | |
| 分子式 : | C21H20O10 | |
| 纯度 : | 98% HPLC | |
| 分子量 : | 432.377 | |
| MDL号 : | MFCD00017456 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 60 mg/mL(138.77 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Vitexin exhibits inhibition of carbohydrate hydrolase with IC50 of 244 μM and shows antioxidant activity in DPPH bleaching assay (IC50 = 92.5 μM [0.4 μg/mL])[3]. It is an apigenin flavone c-glycosidea isolated and purified from the seeds of Vitex trifolia L. with antinociceptive, antimyeloperoxidase, and anti-inflammatory activities[4]. The MCAO (middle cerebral artery occlusion)-induced brain infarction was obviously decreased by vitexin. Vitexin suppressed the autophagy dysfunction to attenuate MCAO-induced cerebral ischemic stroke via mTOR/Ulk1 pathway[5]. Vitexin inhibited growth and induced apoptosis of ACHN and OS-RC-2 cells in a dose-dependent manner, and promoted excessive autophagy by reducing p62 levels and increasing Beclin1 and LC3II levels[6]. The systemic administration of vitexin (1.25; 2.5 and 5 mg/kg; i.p.) exhibited selective protection against chemically-induced seizures. The higher dose of vitexin protected 100% of animals against the tonic-clonic seizures triggered by GABA antagonists. The results from open-field, elevated plus-maze, and light-dark box tests indicated the anxiolytic properties of vitexin at similar range of doses described for the anticonvulsant action screening[7]. Vitexin protected melanocytes from oxidative stress by activating MAPK-Nrf2/ARE signaling pathway[8]. Vitexin was not cytotoxic (IC50 > 200 µg/ml) in RAW 264.7 and at all doses tested it effectively reduced leukocyte migration in vivo, particularly neutrophils in the peritoneal lavage, independently of the inflammatory stimulus used. It also reduced TNF-α, IL-1β and NO releases in the peritoneal cavity of LPS-challenged mice. Vitexin had low cytotoxicity and was able to reduce the releases of TNF-α, IL-1β, NO, PGE2 and increase in IL-10 release by LPS activated RAW 264.7 cells. Vitexin was also able to regulate transcriptional factors for pro-inflammatory mediators, reducing the expression of p-p38, p-ERK1/2 and p-JNK in LPS-elicited cells[9]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01647984 | Ventricular and Atrial Extrasy... 展开 >>toles 收起 << | Phase 4 | Completed | - | Italy ... 展开 >> Ambulatorio Ipertensione e Unità Coronarica Federico II University Naples, Italy, 80131 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.31mL 0.46mL 0.23mL |
11.56mL 2.31mL 1.16mL |
23.13mL 4.63mL 2.31mL |
| 参考文献 |
|---|